Senti Biosciences, Inc. – NASDAQ:SNTI
Senti Biosciences stock price today
$1.6
-2.32
-59.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Senti Biosciences stock price monthly change
+1125.00%
month
Senti Biosciences stock price quarterly change
+1125.00%
quarter
Senti Biosciences stock price yearly change
+562.16%
year
Senti Biosciences key metrics
Market Cap | 18.03M |
Enterprise value | 8.19M |
P/E | -0.52 |
EV/Sales | 1.45 |
EV/EBITDA | -0.10 |
Price/Sales | 5.08 |
Price/Book | 0.22 |
PEG ratio | N/A |
EPS | -1.44 |
Revenue | N/A |
EBITDA | -47.9M |
Income | -64.44M |
Revenue Q/Q | -100% |
Revenue Y/Y | -37.83% |
Profit margin | -1054.57% |
Oper. margin | -1660.75% |
Gross margin | 0% |
EBIT margin | -1660.75% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSenti Biosciences stock price history
Senti Biosciences stock forecast
Senti Biosciences financial statements
| Jun 2023 | 937K | -18.69M | -1995.41% |
|---|---|---|---|
| Sep 2023 | 255K | -14.92M | -5852.16% |
| Dec 2023 | 333K | -18.71M | -5620.42% |
| Mar 2024 | 0 | -12.11M |
| 2025 | 23.63M | -81.67M | -345.57% |
|---|---|---|---|
| 2026 | 3.8M | -25.73M | -677.26% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.48 | -0.25 |
|---|---|---|
| 2024-03-21 | -0.23 | -0.42 |
| 2024-05-09 | -0.23 | -0.26 |
| Jun 2023 | 143630000 | 46.21M | 32.18% |
|---|---|---|---|
| Sep 2023 | 131766000 | 48.83M | 37.06% |
| Dec 2023 | 119484000 | 52.57M | 44% |
| Mar 2024 | 102185000 | 46.09M | 45.11% |
| Jun 2023 | -13.67M | 18.33M | 281K |
|---|---|---|---|
| Sep 2023 | -15.37M | 21.14M | -23K |
| Dec 2023 | -7.03M | 101K | 556K |
| Mar 2024 | -11.68M | -15K | 0 |
Senti Biosciences alternative data
| Aug 2023 | 122 |
|---|---|
| Sep 2023 | 122 |
| Oct 2023 | 122 |
| Nov 2023 | 122 |
| Dec 2023 | 122 |
| Jan 2024 | 122 |
| Feb 2024 | 122 |
| Mar 2024 | 48 |
| Apr 2024 | 48 |
| May 2024 | 48 |
| Jun 2024 | 48 |
| Jul 2024 | 48 |
Senti Biosciences other data
11.45%
-17.11%
of SNTI is owned by hedge funds
13
-13
2.98M
-9.41M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | DYNAMICS SPONSOR LLC director, 10 percent owner | Class B Common Stock | 5,750,000 | N/A | N/A | ||
Option | DYNAMICS SPONSOR LLC director, 10 percent owner | Common Stock | 5,750,000 | N/A | N/A | ||
Option | FAROKHZAD OMID director | Class B Common Stock | 5,750,000 | N/A | N/A | ||
Option | FAROKHZAD OMID director | Common Stock | 5,750,000 | N/A | N/A | ||
Option | EPSTEIN DAVID R director | Class B Common Stock | 112,519 | N/A | N/A |
-
What's the price of Senti Biosciences stock today?
One share of Senti Biosciences stock can currently be purchased for approximately $1.6.
-
When is Senti Biosciences's next earnings date?
Unfortunately, Senti Biosciences's (SNTI) next earnings date is currently unknown.
-
Does Senti Biosciences pay dividends?
No, Senti Biosciences does not pay dividends.
-
How much money does Senti Biosciences make?
Senti Biosciences has a market capitalization of 18.03M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 40.25% to 2.56M US dollars. Senti Biosciences made a loss 92.92M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.
-
What is Senti Biosciences's stock symbol?
Senti Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "SNTI".
-
What is Senti Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Senti Biosciences?
Shares of Senti Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Senti Biosciences have?
As Jul 2024, Senti Biosciences employs 48 workers.
-
When Senti Biosciences went public?
Senti Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 26 May 2021.
-
What is Senti Biosciences's official website?
The official website for Senti Biosciences is sentibio.com.
-
Where are Senti Biosciences's headquarters?
Senti Biosciences is headquartered at 2 Corporate Drive, South San Francisco, CA.
-
How can i contact Senti Biosciences?
Senti Biosciences's mailing address is 2 Corporate Drive, South San Francisco, CA and company can be reached via phone at +65 03823281.
Senti Biosciences company profile:
Senti Biosciences, Inc.
sentibio.comExchange:
NASDAQ
Full time employees:
48
Industry:
Biotechnology
Sector:
Healthcare
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
2 Corporate Drive
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001854270
ISIN: US81726A1007
CUSIP: 81726A100
